

Press release October 18, 2007

Changed date for the Q3 2007 report

The reporting date for the Orexo interim report January-September 2007 has been changed. The report will now be published on October 23, 2007.

For further information, please contact:

Zsolt Lavotha, President and CEO

Tel: +46-18-780 88 12, e-mail: zsolt.lavotha@orexo.com

Claes Wenthzel, Executive Vice President and CFO

Tel: +46-18-780 88 44, e-mail: claes.wenthzel@orexo.com

NOTES TO EDITORS:

About Orexo

Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them. By combining approved active substances with Orexo's drug delivery technologies it is possible to significantly enhance their therapeutic value, such as providing quicker onset of action or ease of administration. This business model is aimed at bringing products to market faster with lower development risk and costs

Orexo, which has its global headquarters and development laboratories in Sweden, currently operates across the world through development, licensing and distribution agreements in all major markets.

Orexo has a balanced portfolio with two products on the market, three in registration and/or late stage clinical phase, one in clinical phase I, and three under formulation development.

Orexo is listed on the OMX Nordic List Mid Cap (ticker: ORX).

www.orexo.com